DOCSLIB.ORG

Orbimed Partners

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Orbimed Partners The Biotech Growth Trust Annual General Meeting July 2021 This document does not constitute an offer to sell, or the solicitation of an offer to purchase, any security or fund, including shares of the Biotech Growth Trust PLC (the “Fund”). Any such offer may only be made by means of a prospectus or other appropriate offering document. This presentation is as of the date noted above and may be changed without notice. © 2021 OrbiMed Advisors LLC. All Rights Reserved. CONFIDENTIAL 1 BIOG Performance since Inception 18 May 2005 through 30 June 2021 £1,600 £ % BIOG +1333.5% £1,400 BIOG NAV (£) NBI (£) FTSE (£) £1,200 NBI £1,000 +902.3% £800 16 Years £600 £400 FTSE +188.2% £200 £0 Source: Frostrow, Bloomberg. Note: See Endnotes for additional information, including with regard to the calculation of these results and the index shown above. BIOG June NAV return figures are estimates as provided by Frostrow/Morningstar as of July 1, 2021. © 2021 OrbiMed Advisors LLC. All Rights Reserved. CONFIDENTIAL 2 Proven Health Flexible 25+ year strong 100% healthcare, Investing across returns across including stages, sub- public and private biopharma, devices, sectors, equity and debt Global diagnostics, digital Leader geographies and markets health, services capital structures 11 locations, ~$20 billion AUM including New York, ~100 San Francisco, professionals Hong Kong, Shanghai, Mumbai, ~15 former Herzliya CEOs/founders 128 20+ 30 Global New Hires Colleagues with Employees in 2020/21 M.D. / Ph.D. Past performance is no guarantee of future results. Assets Under Management estimated as of 30 June 2021 © 2021 OrbiMed Advisors LLC. All Rights Reserved. CONFIDENTIAL 3 OrbiMed – BIOG Investment Team Geoffrey Hsu, CFA Portfolio Manager (since 2005) A.B. Chemistry, Harvard University M.D. Program, Harvard Medical School (2 years) M.B.A: Harvard University Prior: Lehman Brothers Alexandria Huynh, Ph.D. Raj Patel Biotechnology Biotechnology B.S.: Biology, CSU Los Angeles BSE: Chemical Engineering, University of Michigan Ph.D.: Immunology, Harvard University Prior: Leerink Prior: Cowen Seth Cassel, M.D., Ph.D. Jingren Deng, Ph.D. Biotechnology Biotechnology M.P.H.: Epidemiology & Biostatistics, Boston University A.B.: Biology, Harvard University M.B.A.: Health Sector Management, Boston University M.D.: Harvard Medical School Ph.D.: Biological Sciences, Virginia Tech Ph.D.: Biological & Biomedical Sciences, Harvard Medical School Xavier Cheng, Ph.D. Charlie Steinman Biotechnology Life Science Tools & Diagnostics B.Sc.: Biological Chemistry, University of Toronto B.S.: Finance & Accounting, Georgetown University Ph.D.: Analytical Chemistry, University of Toronto Prior: Goldman Sachs, BMO Capital Markets Prior: L.E.K Consulting Iris (Ting) Wang, CFA Niko Liu Emerging Markets Emerging Markets B.S.: Biological Sciences, Peking University B.S.: Finance, Nankai University M.B.A: Columbia University M.S.: Finance, Chinese University of Hong Kong Prior: Credit Suisse, McKinsey, A.T. Kearney Prior: Credit Suisse, Jefferies Tianqi Leng, Ph.D. Claire Hu Emerging Markets Emerging Markets B.S.: Biological Sciences, Peking University B.S.: Finance, Shanghai Jiao Tong University Ph.D.: Clinical Medicine, University of Oxford Prior: JPM China Healthcare Investment Banking Prior: Merck KGaA © 2021 OrbiMed Advisors LLC. All Rights Reserved. CONFIDENTIAL 4 Investment Themes © 2021 OrbiMed Advisors LLC. All Rights Reserved. CONFIDENTIAL 5 Innovation – Pipeline as Full as it’s Ever Been “Golden era” of innovation increasing number of drugs in development Number of Late-Stage Pipeline Products by Therapeutic Area (2010-2020) +50% Source: IMS, © 2021 IQVIA. All Rights Reserved. IQVIA market research information used in this report is proprietary to IQVIA and available on a confidential basis by subscription from IQVIA. IQVIA market research information reflects estimates of marketplace activity and should be treated accordingly. © 2021 OrbiMed Advisors LLC. All Rights Reserved. CONFIDENTIAL 6 Novel Technologies at Early Stages of Reaching the Market Cell Therapy Marketed Products Gene Therapy/Editing Nucleic Acid Therapies (DNA/RNA) Multivalent Antibodies and Cell Engagers Therapeutic Vaccines Only a few drugs have been approved based on each novel technology thus far, with hundreds of additional candidates in clinical trials Note: examples may not be representative of portfolio holdings © 2021 OrbiMed Advisors LLC. All Rights Reserved. CONFIDENTIAL 7 Notable New Drug Approvals Address Large Markets Gene Therapy for Protein Modulation Antibody for Alzheimer’s Antibody Drug Conjugate Long Acting Antibody Spinal Muscular Atrophy for Cystic Fibrosis Disease for Breast Cancer for PNH (rare) $2.0bn peak sales $9.5bn peak sales $9.4bn peak sales $4.0bn peak sales $4.1bn peak sales Polymerization Inhibitor Fusion Protein RNA Interference for Antibody for Thyroid Eye Antibody Drug Conjugate for Sickle Cell Disease for Beta-Thalassemia Amyloidosis Disease for Bladder Cancer $2.1bn peak sales $2.3bn peak sales $1.1bn peak sales $3.3bn peak sales $3.0bn peak sales Note: examples may not be representative of fund holdings, estimates as of June 2021. Source: peak sales estimates are from various sources including company reports, Bloomberg, Visible Alpha, and First Order Analytics © 2021 OrbiMed Advisors LLC. All Rights Reserved. CONFIDENTIAL 8 FDA Regulatory Climate Expected to Remain Favorable COVID-related delays should resolve over time Former President Trump’s administration supported FDA policies to expedite drug approvals as a means of increasing competition to manage drug pricing: • More frequent & earlier engagement with companies to streamline development • More flexible efficacy/safety standards for FDA approvals • Increased use of biomarkers and surrogate endpoints • Lower the time and cost to develop new drugs Janet Woodcock became Acting FDA commissioner under Biden in January • Senior FDA official with about 35 years of agency experience • Would like to become permanent head and has support from industry • Other leading candidate is Michelle McMurry-Heath, President of BIO trade organization • Unclear when Biden will make a formal appointment, but new head likely industry- friendly Some unexpected drug rejections and regulatory delays so far in 2021, but we do not believe this reflects a new risk-averse stance at the FDA • Volume of investigational new drug applications has been increasing; some COVID- related inspection delays • 1Q21 drug approvals represented the most new drugs ever approved by FDA in 1Q • Aducanumab Alzheimer’s treatment approved despite mixed dataset Appointment of permanent FDA commissioner and end of COVID-related delays should allow constructive FDA policies to continue to benefit the biotech industry Source: AgencyIQ, Scott Gottlieb speeches, fda.gov © 2021 OrbiMed Advisors LLC. All Rights Reserved. CONFIDENTIAL 9 FDA Supporting the Innovation Engine As of 12/31/2020 FDA push for drug approvals led to another strong year in 2020 FDA New Molecular Entity Approvals 60 50 40 30 59 53 48 45 46 20 39 41 36 30 27 27 24 24 26 10 21 20 22 21 22 17 18 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 Source: FDA, Washington Analysis © 2021 OrbiMed Advisors LLC. All Rights Reserved. CONFIDENTIAL 10 Biotech M&A Business development activities continued despite COVID, takeouts still occurring Announced Public Biotech M&A Transactions $21B 6 Deals $88B $58B 5 Deals 5 Deals $33B 4 Deals $25B $6B $6B 3 Deals 3 Deals 3 Deals $10B $7B $73B $3B $2B 2 Deals 2 Deals 2 Deals 2 Deals 2 Deals 0 Deals Q1'2018 Q2'2018 Q3'2018 Q4'2018 Q1'2019 Q2'2019 Q3'2019 Q4'2019 Q1'2020 Q2'2020 Q3'2020 Q4'2020 Q1'2021 Source: Jefferies, Bloomberg • Encouragingly, despite work-from-home conditions, M&A and customary business development activities (licensing, partnerships) have continued throughout the COVID pandemic Selected biotech acquisitions • AstraZeneca’s $39.1bn acquisition of Alexion Pharmaceuticals (36% premium) • Bristol-Myers’ $13.1bn acquisition of MyoKardia (77% premium) • Merck’s $1.5bn acquisition of Pandion Therapeutics (196% premium) • Amgen’s $1.6bn acquisition of Five Prime Therapeutics (77% premium) • Gilead’s $21.0bn acquisition of Immunomedics (111% premium) Source: Bloomberg | deal premiums based on last 20 trading days average price prior to deal announcement. © 2021 OrbiMed Advisors LLC. All Rights Reserved. CONFIDENTIAL 11 Strong Biotech IPO Market over Past Few Years Number of IPOs and funds raised have increased markedly Biotech IPOs – Count by Quarter 30 27 26 25 24 21 20 20 20 18 17 16 15 14 14 15 13 11 11 11 10 10 10 10 10 9 10 8 8 7 7 7 6 6 5 5 5 4 5 3 3 3 3 2 2 2 2 1 0 Source: BofA Securities as of 1 July 2021 • Since the beginning of 2018, over 200 new biotech companies have gone public. We estimate that the investable universe in biotech worldwide is over 1,500 companies. • The Biotech Growth Trust has been actively participating in these IPOs (and selected crossovers), as many of these companies have the most cutting-edge technologies © 2021 OrbiMed Advisors LLC. All Rights Reserved. CONFIDENTIAL 12 Biotech Opportunities Emerging in China Innovation emerging in second largest pharmaceutical market in the world Number of Early-Stage Pipeline Drugs by Company Headquarters Location Over Time and Country Share Source: IQVIA Institute, Global Trends in R&D report, May 2021 China is emerging as a source of innovation in biotech • In 2015, the Chinese government committed to building a biotech ecosystem
Load more

Recommended publications
  • RRP Sector Assessment
    OrbiMed Asia Partners III, LP Fund (RRP REG 51072) OWNERSHIP, MANAGEMENT, AND GOVERNANCE A. The Fund Structure 1. The Asian Development Bank (ADB) proposes to invest in OrbiMed Asia Partners III, LP Fund (OAP III), which is a Cayman Islands exempted limited partnership seeking to raise up to $500 million in capital commitments. It is managed by OrbiMed Asia GP III, LP (the general partner), a Cayman Islands exempted limited partnership. The sole limited partner of the general partner is OrbiMed Advisors III Limited, a Cayman Islands exempted company. OrbiMed Advisors LLC (the investment advisor), a registered investment advisor with the United States (US) Securities and Exchange Commission, will provide investment advisory services to OAP III. This structure is illustrated in the figure below. Table 1 shows the ultimate beneficial owners (UBOs) of the general partner and the investment advisor. Table 1: Ultimate Beneficial Owners of the General Partner and the Investment Advisor (ownership stake, %) Name Investment Advisor General Partner Sven H. Borho (~10–25%) (~8%) Alexander M. Cooper (~8%) Carl L. Gordon (~10–25%) (~8%) (also Director) Geoffrey C. Hsu (<5%) (~8%) Samuel D. Isaly (~50–75%) (~8%) W. Carter Neild (<5%) (~8%) (also Director) Jonathan T. Silverstein (~5–10%) (~8%) (also Director) Sunny Sharma (~8%) (also Officer) Evan D. Sotiriou (~8%) David G. Wang (~8%) (also Officer) Jonathan Wang (~8%) (also Officer) Sam Block III (~8%) Source: OrbiMed Group. 2 2. Investors. The fund held a first closing of approximately $233.5 million on 1 March 2017, and a second closing of approximately $137.6 million on 26 April 2017.
    [Show full text]
  • Israel's Life Sciences Industry IATI Report 2017
    With the support of Israel’s Life Sciences Industry IATI Report 2017 Connecting Israel’s Tech Ecosystem ISRAEL'S UMBRELLA ORGANIZATION for the High-Tech and Life Science Industries Connecting the tech ecosystem IATI.CO.IL To learn more about joining IATI: T: +972 73713 6313 / [email protected] / www.iati.co.il Herzliya Pituach, Israel Dear Friends, The IATI 2017 Report: Israel’s Life Sciences Industry offers a sweeping panorama of the country’s flourishing life sciences industry, which is growing in prominence in the global healthcare market. The report provides a snapshot of various aspects of the industry, from current trends and influences to systematic elements including continued government support and academic excellence. The Israeli Life Sciences Industry has accelerated rapidly, with a growing pipeline in a variety of industry segments. This growth is aided by consistent government support and a strong academic base, which is a leading source for companies and technologies within the ecosystem. We at IATI, Israel’s Umbrella Organization of the High-Tech & Life Science industries, believe that the combination of the country’s experienced and highly-educated professionals, an outstanding academic community, innovative spirit and technological prowess will only propel Israel’s life sciences industry even further in the coming years. We expect more cooperation between multinational and local players to bring revolutionary treatments and solutions to people around the world. This unique report provides an in-depth view of the local industry, highlighting the sustained growth and progress that was made and help give readers an idea of where the industry is headed.
    [Show full text]
  • Orbimed Launches $924 Million Royalty & Credit Opportunities Fund
    OrbiMed Launches $924 Million Royalty & Credit Opportunities Fund NEW YORK, January 30, 2015 – OrbiMed, a leading investment firm focused on the healthcare sector, today announced the closing of its second healthcare royalty and credit opportunities Fund, OrbiMed Royalty Opportunities II, LP, with $924 million in commitments, including $24 million from the General Partner. Investors in the fund include a broad range of premier endowment, foundation, pension and other institutional investors. Consistent with its predecessor, the new fund will acquire healthcare royalty streams and provide tailored debt capital solutions to healthcare companies and institutions worldwide. The Fund expects to commit between $20 million to $150 million per investment, with the ability to commit larger amounts in collaboration with other OrbiMed funds. “OrbiMed is active across a broad range of worldwide healthcare investing, including royalty and credit opportunities, public equity, and private equity. Interest in this fund reflects the strong appeal of the OrbiMed strategy and our $14 billion global platform,” said Samuel D. Isaly, Managing Partner. “We are grateful for strong support from the LP community, which made for an efficient fundraise that exceeded our target with just a single closing,” said W. Carter Neild, a Partner at OrbiMed. “We are particularly excited to welcome a dozen leading medical research and healthcare institutions as investors. OrbiMed looks forward to a strategic, collaborative relationship with them going forward.” "We offer structured capital solutions, including combinations of royalty, debt, and equity financing, that provide companies and institutions another tool to solve their capital needs while also bringing them into the OrbiMed family," noted Tadd Wessel, a Managing Director at OrbiMed.
    [Show full text]
  • Orbimed Asia Partners III, L.P. Form D/A Filed 2017-09-06
    SECURITIES AND EXCHANGE COMMISSION FORM D/A Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act. [amend] Filing Date: 2017-09-06 SEC Accession No. 0001012975-17-000673 (HTML Version on secdatabase.com) FILER OrbiMed Asia Partners III, L.P. Mailing Address Business Address 601 LEXINGTON AVENUE 601 LEXINGTON AVENUE CIK:1685093| IRS No.: 000000000 | State of Incorp.:E9 | Fiscal Year End: 1231 54TH FLOOR 54TH FLOOR Type: D/A | Act: 33 | File No.: 021-281414 | Film No.: 171071170 NEW YORK NY 10022 NEW YORK NY 10022 212-739-6400 Copyright © 2017 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB APPROVAL OMB Number: 3235-0076 Washington, D.C. 20549 June 30, Expires: FORM D 2012 Estimated average burden hours per 4.00 Notice of Exempt Offering of Securities response: 1. Issuer's Identity CIK (Filer ID Number) Previous Name(s) ☒ None Entity Type 0001685093 ☐Corporation Name of Issuer ☒ Limited Partnership OrbiMed Asia Partners III, L.P. ☐ Limited Liability Company Jurisdiction of Incorporation/ Organization ☐ General Partnership CAYMAN ISLANDS ☐ Business Trust Year of Incorporation/Organization ☐Other ☐ Over Five Years Ago ☒ Within Last Five Years (Specify Year) 2016 ☐ Yet to Be Formed 2. Principal Place of Business and Contact Information Name of Issuer OrbiMed Asia Partners III, L.P. Street Address 1 Street Address 2 601 LEXINGTON AVENUE 54TH FLOOR City State/Province/Country ZIP/Postal Code Phone No.
    [Show full text]
  • OTONOMY, INC. (Name of Issuer)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* OTONOMY, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 68906L105 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP IV LLC Samuel D. Isaly 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) August 12, 2014 (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7(b) for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
    [Show full text]
  • 3Rd FCF Life Science Venture Capital Report
    FCF Life Science Research 3rd Life Science Venture Capital Report – Financing Trends in Europe and the US Fungi Penicillium Part of FCF Life Science Research Series Executive Summary FCF Overview Funding Development in 2018 Life Sciences: A closer Look C r o s s - border Investment Activity Investor Analysis Life Science Exits 2 Executive Summary The FCF Life Science Venture Capital FCF Life Science Venture Capital Report Recipients Report is a is a comprehensive, standardized analysis for biotechnology, The FCF Life Science Venture Capital Report targets the following standardized report pharmaceutical and medical technology companies, examining recipients: focusing on venture recent venture capital deal trends in the European life science ▪ Corporates / Executives ▪ Venture capital investors capital deal industry ▪ Institutional investors ▪ Family Offices / High- characteristics in the ▪ Private equity investors net-worth individuals biotechnology, ▪ Advisors Selection of Companies pharmaceutical and medical technology The selection of companies is based on the following criteria: Availability segments, and can be used as a quick ▪ Companies operating in the biotechnology, pharmaceutical, The FCF Life Science Venture Capital Report is available on FCF’s reference for medical technology, services or other life science related sectors website at “https://www.fcf.de/de/research/life-science-research“ investors, corporates ▪ Sole focus on transactions involving European life science and professionals companies Data ▪ The therapeutics sector is further divided into the following All input data is provided by Pitchbook, S&P Capital IQ or More advanced, indications: Oncology, Central Nervous System, Infectious GlobalData and is not independently verified by FCF. Ratio and detailed and / or Diseases, Immunology, Ophthalmology, Rare Diseases, multiple calculations are driven based on the input data available.
    [Show full text]
  • FCF Life Science Venture Capital Monitor
    FCF Fox Corporate Finance | FCF Life Sciences Life Sciences Venture Capital Monitor – Europe February 2021 Antibody Agenda FCF LIFE SCIENCES OVERVIEW FCF Life Sciences Overview Overview Services Facts and Figures Focus on Biotech, MedTech and HealthTech Collaboration Over Over Life Sciences with Management Team of 100 years EUR 2bn We advise innovative companies on arranging, structuring and placing equity BioScience Presentation 10 in aggregated Life Sciences and debt transactions in a holistic financing approach. Valuation and Life Sciences transaction based in Munich Integrated YAFO Capital experience volume1 Financial Modeling Focus Areas Over Post- Access to 7 Transaction 80 Leading > 1500 regularly FCF advises with its dedicated Life Sciences team on the following Support completed Life published Life international EIB advisor transaction types: Sciences Sciences Investor investors in Europe Screening transactions1 reports 1 including Professionals and Life Sciences Advisors Investor / IB Venture China Roadshow Equity Life Sciences Research Series Debt Licensing Due Diligence Support Life Sciences Venture Biotech Venture Capital Monitor – US Equity & Debt Capital Monitor – Europe Life Sciences Team Fundraising Financing Strategy Advisory Life Sciences Venture Biotech Licensing Capital Report Monitor – China Closing Assistance Prof. Dr. Arno Fuchs Dr. Alexandra Dr. Joachim Alexander Kuhn Horst Domdey CEO Goll M. Greuel Analyst Life Sciences Life Sciences Life Sciences Term Sheet Advisor Advisor Advisor Negotiation Biotech Public Equity
    [Show full text]
  • Orbimed Announces New General Partner
    OrbiMed Announces New General Partner NEW YORK, February 3, 2020 – OrbiMed is pleased to announce the promotion of David Bonita, M.D., to General Partner. David joins the firm’s six existing General Partners, Sven H. Borho, Carl Gordon, Jonathan Silverstein, Carter Neild, Geoffrey Hsu and Scot Stevens. Since joining OrbiMed in 2004, David has led numerous transformative investments in innovative biopharmaceutical and medical device companies, including Loxo Oncology, Tricida, Cryterion Medical, and Therachon SAS, among others. “David’s investments have contributed significantly to the financial returns enjoyed by OrbiMed’s clients, but more importantly his companies have discovered and developed numerous therapies that treat life- threatening unmet medical needs.” stated Jonathan Silverstein, a Managing Partner of OrbiMed. “David’s promotion to General Partner is a recognition of his extraordinary contributions to the firm in recent decades,” stated Managing Partner Carl Gordon. “We look forward to his growing organizational leadership in the years to come.” David can be reached at (212) 739-6400 or [email protected] About OrbiMed OrbiMed is a leading healthcare investment firm, with $13 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, utilizing a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed maintains offices in New York City, San Francisco, Shanghai, Hong Kong, Mumbai and Herzliya. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. Contact Carter Neild, CFA Phone: (212) 739.6400 Email: [email protected] www.OrbiMed.com OrbiMed Advisors LLC.
    [Show full text]
  • Private Equity Analyst
    PRIVATE EQUITY ANALYST NOVEMBER 2020 Women to Private Equity’s Top Female Talent of Today and Tomorrow p. 7 10 VCs Grooming Game-Changing Startups p. 13 Watch LP Cycles Ad HFA+PEA-Ltr DR080420.pdf 1 8/4/20 5:43 PM Private equity investing has its cycles. Work with a secondary manager who’s C experienced them all. M Y CM MY As leaders of the secondary market, the Lexington Partners team CY draws on more than 400 years of private equity experience. CMY Through all types of business cycles, we have completed over K 500 secondary transactions, acquiring more than 3,000 interests managed by over 750 sponsors with a total value in excess of $53 billion. Our team has excelled at providing customized alternative investment solutions to banks, financial institutions, pension funds, sovereign wealth funds, endowments, family offices, and other fiduciaries seeking to reposition their private investment portfolios. If you have an interest in the secondary market, our experience is second to none. To make an inquiry, please send an email to [email protected] or call us at one of our offices. Innovative Directions in Alternative Investing New York • Boston • Menlo Park • London • Hong Kong • Santiago • Luxembourg www.lexingtonpartners.com Includes information regarding six funds managed by Lexington’s predecessor formed during the period 1990 to 1995. This information is provided for informational purposes only and is not an offer to sell or solicitation of offers to purchase any security. Private Equity Analyst November 2020 contents Volume XXX, Issue 11 Fund News u The Roundup Comment Clayton Dubilier Collects About $14B for Latest Buyout Fund 26 H.I.G.
    [Show full text]
  • Semi-Annual Market Review
    Semi-Annual Market Review HEALTH IT & HEALTH INFORMATION SERVICES JULY 2020 www.hgp.com TABLE OF CONTENTS 1 Health IT Executive Summary 3 2 Private Equity Survey 5 3 Health IT Market Trends 10 4 Health IT M&A (Including Buyout) 13 5 Health IT Capital Raises (Non-Buyout) 18 6 Healthcare Capital Markets 19 7 Macroeconomics 23 8 Health IT Headlines 25 9 About Healthcare Growth Partners 28 10 HGP Transaction Experience 29 11 Appendix A – M&A Highlights 32 12 Appendix B – Buyout Highlights 35 13 Appendix C – Investment Highlights 37 Copyright© 2020 Healthcare Growth Partners 2 EXECUTIVE SUMMARY 1 COVID-19 has quickly and permanently changed the way business is conducted around the world. Health IT was no exception, as providers rapidly shifted to virtual care delivery models enabled by new CMS rules and technology that equips the American healthcare system with maximum flexibility to respond to the COVID-19 pandemic. Together, these innovations accelerated the transformational shift to “hospitals without walls”. While the Health IT and broader Healthcare industry have undoubtedly received renewed attention during this public health crisis and will experience a long- term lift, we have also observed a slowdown in the pace of transaction activity, albeit a more measured slowdown when compared to that of other industries. The underlying sentiment for Health IT is as strong as ever, as evident in our Private Equity Survey (beginning page 5). The following six measures of Health IT activity during the first half of 2020 reflect the challenges of the lockdown but overall reflect how Health IT continues to receive high investor interest due to overwhelmingly strong fundamentals during this tough economic environment.
    [Show full text]
  • May 9, 2018 Orbimed Announces New General Partner
    OrbiMed Announces New General Partner NEW YORK, May 9, 2018 – OrbiMed is pleased to announce the promotion of C. Scotland Stevens to General Partner. Scot joins the firm’s five existing General Partners, Sven H. Borho, Carl L. Gordon, Jonathan T. Silverstein, W. Carter Neild and Geoffrey C. Hsu. Scot joined OrbiMed in 2005 from Goldman, Sachs & Co., and in recent years has led the firm’s trading activities and derivatives investment strategies. Scot has provided strong leadership across the firm, in particular for OrbiMed’s public equity and hedge fund team. The addition of Scot as a General Partner is an expression of OrbiMed's commitment to strengthening the organization for the long term. “Scot is a consummate professional and team leader, elevating those around him.” said Managing Member Sven H. Borho. “We are proud to have him as a new General Partner and leader of the firm.” Scot can be reached at (212) 739-6400 or [email protected]. About OrbiMed OrbiMed is a leading healthcare investment firm, with $14 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, utilizing a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed maintains offices in New York City, San Francisco, Shanghai, Hong Kong, Mumbai and Herzliya. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and global team resources and support to help build world-class healthcare companies. Contact W. Carter Neild, CFA Phone: (212) 739.6400 Email: [email protected] www.OrbiMed.com OrbiMed Advisors LLC.
    [Show full text]
  • A Primer for Development Finance and Philanthropic Funders
    ReDesigning Development Finance Initiative A joint initiative of the World Economic Forum and the OECD Blended Finance Vol. 1: A Primer for Development Finance and Philanthropic Funders An overview of the strategic use of development finance and philanthropic funds to mobilize private capital for development July 2015 Contents Acknowledgements 3 Preface This Report synthesizes the ideas and contributions of hundreds of individuals and organizations, to whom we are 4 Executive Summary extremely thankful for generously contributing their time, energy and insights. 6 Financing an Ambitious Sustainable Development Agenda We would like to acknowledge our partners in the ReDesigning 8 Blended Finance: An Opportunity to Unlock Wider Development Finance Initiative Report, the OECD Development Actors and Resources for Development Assistance Committee, who have tirelessly lent their time and insights to the project. In particular, we would like to 8 3.1 Defining Blended Finance recognize Erik Solheim, Haje Schütte, Jens Sedemund and Kaori Miyamoto. A special thanks also goes out to our Report 9 3.2 Why is Blended Finance Important? partners, Monitor Deloitte, for their continuous support and 10 The Role of Blended Finance engagement on this document. Furthermore, we would like to acknowledge the insights and contributions of the ReDesigning 10 4.1 Overcoming Barriers to Private Capital in Development Finance Initiative Steering Committee: Emerging and Frontier Markets Chair: Christian Paradis, Minister of International Development and La Francophonie
    [Show full text]